See what we know about VITT, a rare blood coagulation disorder-nationwide

The new blood coagulation syndrome found in a small number of COVID-19 vaccinated people continues to receive a great deal of attention, but experts claim that the event is extremely rare and treatable in most cases.

Vaccine-induced thrombotic thrombocytopenia (VITT) has been identified in at least 18 Oxford-AstraZeneca recipients in Canada and is under consideration in an additional 10 people. There were three deaths associated with this condition.

read more:

See who the state plans to vaccinate for COVID-19 in the coming weeks

This disorder, which is characterized by low platelet counts, is associated with viral vector shots from AstraZeneca and Johnson & Johnson, but not explicitly.

Some states have begun to stop using AstraZeneca for their first dose. Pfizer, Canada-The increased supply of mRNA vaccines from BioNTech and Moderna means that more Canadians are getting access to these shots.

The story continues under the ad

Here’s what we know about VITT:

How often does it occur?

The National Advisory Board on Immunization (NACI) states that the proportion of VITT in Canada is close to once for every 100,000 doses given as of 28 April.

In Canada, more than 2 million doses of AstraZeneca have been administered. Last week, Ontario said the state’s risk was close to 1 in 60,000.

Click to play the video:'Major General. Fortin is holding a military investigation.

Maj. Gen. Fortin suspends military investigation

Maj. Gen. Fortin suspends military investigation

According to the Ontario Scientific Table, there are few reports of VITT using the Johnson & Johnson vaccine in the United States, with an incidence of approximately 1 per 500,000 doses administered.

AstraZeneca is not approved in the United States and Johnson & Johnson is approved in Canada but has not yet been used here.

The story continues under the ad

What is the cause of VITT?

According to experts, this disorder appears to be an immune response to viral vector vaccines. Antibodies are produced within 4 to 28 days of jabs, so a small number of people somehow turn on platelets.

It is not clear why a small number of recipients are affected and others are not.

According to experts, previous blood clots and family history of blood clots do not seem to be important, and they may not be taking oral contraceptives. This carries about 5 out of 10,000 people at risk of coagulation.

Gender also does not seem to indicate who is susceptible to VITT.

What are the symptoms to watch out for?

A number of different symptoms may indicate VITT. NACI initially stated that it would monitor for signs between 4 and 20 days after receiving the viral vector vaccine, but recently extended its timeline from 4 to 28 days.

read more:

First-time recipients of AstraZeneca vaccine in limbo after some states have pushed a pause

Symptoms include persistent and severe headaches, difficulty moving parts of the body, seizures, blurred vision or diplopia, shortness of breath, back, chest, or abdominal pain. Significant changes in the limbs (swelling, redness, pale appearance and coldness of the arms and legs) may also indicate coagulation.

The story continues under the ad

Blood clots usually appear in the head, lungs, legs, or stomach, so symptoms associated with these body parts should not be ignored. Some VITT blood clots are found in parts of the body that are not normally associated with blood clots, such as the liver, spleen, and visceral veins that drain the intestines.

What would you do if you think you have it?

Experts say people should seek medical care if symptoms occur.

The primary care physician (family physician, walk-in clinic, or distance care worker) can provide guidance when symptoms are manageable.

But if they look more serious, head to the emergency room.

Like many other conditions, VITT seems to be easier to handle if detected early.

How is it diagnosed?

The doctor orders a complete blood count (CBC) to determine if the patient has low platelets and then an additional blood test or imaging test (such as an MRI) to detect if a blood clot has formed. to hold.

Click to play video:

Infectious disease specialists address COVID-19 vaccine concerns

Infectious disease specialists address COVID-19 vaccine concerns

How is it treated?

Effective treatments are available, including special types of anticoagulants and drugs that regulate the immune system.

The story continues under the ad

Although rare, experts say that coagulopathy is serious and treatment may be intensive.

Doctors avoid using anticoagulant heparin in VITT cases that appear to be very similar to another disorder called HIT or heparin-induced thrombocytopenia.

View link »

© 2021 The Canadian Press

See what we know about VITT, a rare blood coagulation disorder-nationwide

Source link See what we know about VITT, a rare blood coagulation disorder-nationwide

Related Articles

Back to top button